« A link between Research and Specialised Applications in the field of Biomedical Diagnosis ».


Company's presentation

HYPHEN BioMed is a biotechnology company expanding rapidly. Its major activity is conceiving, developing, manufacturing and marketing research and biomedical in vitro diagnostic reagents for the exploration of Thrombosis, Haemostasis and Auto-Immunity. These reagents are available worldwide, through a network of specialised distributors, or directly from the company (when there is no distributor).

Our laboratories are equipped with analytical instruments and with highly performing manufacturing machines and quality control analyzers. They fit the best to the specialized research and production needs of our company. This equipment is continuously evolving in order to adapt to new needs, and manufacturing the new reagents originated from our research.

HYPHEN BioMed owns a complete range of analytical equipment for immunological, clotting and chromogenic methods. The company has also a full equipment for cell culture, production of recombinant proteins, engineering and purification of proteins from plasma or biological extracts. Manufacturing machines include various lyophilizators, with a full capacity of 8,000 vials per run, and machines for capping and labelling the vials. There are many storage capacities, including cold rooms at 2-8 °C, and ultra-low temperature freezers (- 85 °C).

The company applies a Quality Management System, and is certified ISO 9001: 2000 and ISO 13485 :2003, and complies with all regulatory and legal requirements. The project management system allows conducting a very active research, internal and within various academic and industrial partnerships. New products can then be continuously introduced.

HYPHEN BioMed focuses its work an its development on its know-how and its field of competence. Research and technological collaborations allow the company benefiting of all the complementary technologies which are needed for its progression and growth.

HYPHEN BioMed's philosophy is to work within a network of complementary know-how and competences, in order to provide a full offer. Many collaboration contracts are running with Universities, Research Centres and companies with proprietary technologies complementary to those of the company. Many distribution contracts allow distributing and providing the company’s service worldwide, through specialized scientific network.


HYPHEN BioMed proposes a very complete and in continuous evolution line of reagents for Thrombosis, Haemostasis and Auto-Immunity, including: purified proteins and enzymes, monoclonal and polyclonal antibodies, various immunoconjugates, chromogenic, clotting and immunological kits for research or diagnosis (CE marked). This line allows exploring blood coagulation and fibrinolysis, as well as the Thrombosis associated Auto-Immune disorders.

A specific line of reagents concerns the in-vitro diagnosis and prognosis of thrombotic diseases, and the monitoring of anticoagulant, antithrombotic and fibrinolytic therapies. These reagents are CE marked.

The reagents offered by HYPHEN BioMed are frequently invaluable tools for the pharmaceutical research, and allow testing the efficacy and safety of cardio-vascular drugs currently under development. When a new drug is released, our kits allow adjusting the drug posology and testing its efficacy.

Research reagents are mainly used by academic research (medical centres and university hospitals), epidemiological investigations and pharmaceutical industry.

Diagnostic kits are used by clinical laboratories, coagulation laboratories in university hospitals, and all specialized clinical chemistry laboratories, in hospitals and clinics, where Thrombosis, Haemostasis and Auto-Immunity are explored.

HYPHEN BioMed is a company with high flexibility, which thanks to its know-how and its high reactivity becomes a major partner for research and specialized diagnosis in the field of Thrombosis, Haemostasis and Auto-Immunity.